SAN DIEGO and PENNINGTON, N.J., June
13, 2019 /PRNewswire/ -- OncoSec Medical Incorporated
(OncoSec) (NASDAQ:ONCS), a company developing late-stage
intratumoral cancer immunotherapies, today announced that
Christopher G. Twitty, Ph.D., Chief Scientific Officer,
will present compelling immunological data from multiple clinical
trials using the Company's novel biomarker technology at World
Pharma Week (WPW) 2019 taking place June
17-20 in Boston.
Dr. Twitty's presentation, titled "Reversing Resistance to
Definitive Anti-PD-1 Failures with Intratumoral IL-12 and
Pembrolizumab Combination Therapy," will focus on approaches to
overcome immune resistance mechanisms in cancer, namely
reinvigorating T cell exhaustion with DNA-based cytokines,
chemokines and T cell engaging antibodies.
Specifically, Dr. Twitty's presentation will highlight:
- Immunological data from OncoSec's biomarker program taken from
the OMS-102, KEYNOTE-695 (metastatic melanoma), and KEYNOTE-890
(metastatic triple negative breast cancer) clinical studies;
- Developments associated with OncoSec's visceral lesion
applicator (VLA) and its next-generation plasmids;
- Therapeutic rationale for intratumoral delivery of IL-12 for
treatment across multiple solid tumor types.
The presentation will be made during the Combinations Strategies
and Clinical Trials in Immuno-Oncology track, which is part of
Cambridge Healthtech Institute's Third Annual Clinical Innovation
for Combination Immunotherapy meeting. A link to the meeting's
agenda and speaker panel can be found here.
With more than 1,500 senior delegates and 130 exhibitors slated
for this year's conference, WPW attracts renowned experts across
the global medical sciences community and is dedicated to all
stages of pharmaceutical R&D, from discovery though preclinical
development and translational research to clinical biomarkers.
About OncoSec Medical Incorporated
OncoSec is a clinical-stage biotechnology company focused on
developing cytokine-based intratumoral immunotherapies to stimulate
the body's immune system to target and attack cancer.
OncoSec's lead immunotherapy investigational product candidate –
TAVO™ (tavokinogene telseplasmid) – enables the intratumoral
delivery of DNA-based interleukin-12 (IL-12), a naturally occurring
protein with immune-stimulating functions. The technology, which
employs electroporation, is designed to produce a controlled,
localized expression of IL-12 in the tumor microenvironment,
enabling the immune system to target and attack tumors throughout
the body. OncoSec has built a deep and diverse clinical pipeline
utilizing TAVO™ as a potential treatment for multiple cancer
indications either as a monotherapy or in combination with leading
checkpoint inhibitors; with the latter potentially enabling OncoSec
to address a great unmet medical need in oncology: anti-PD-1
non-responders. Results from recently completed clinical
studies of TAVO™ have demonstrated a local immune response,
and subsequently, a systemic effect as either a monotherapy or
combination treatment approach. In addition to TAVO™, OncoSec is
identifying and developing new DNA-encoded therapeutic candidates
and tumor indications for use with its new Visceral Lesion
Applicator (VLA), to target deep visceral lesions, such as liver,
lung or pancreatic lesions.
For more information, please visit www.oncosec.com.
TAVO™ trademark of OncoSec Medical Incorporated.
CONTACT
Investor Relations:
Will O'Connor
Stern Investor Relations
(212) 362-1200
will@sternir.com
Media Relations:
Katie Dodge
JPA Health Communications
(617) 657-1304
kdodge@jpa.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/oncosec-to-present-immunological-data-at-world-pharma-week-2019-300866943.html
SOURCE OncoSec Medical Incorporated